399 results on '"Nivolumab -- Reports"'
Search Results
352. New Carcinomas Data Have Been Reported by Researchers at Department of Urology (A prospective, open-label, interventional study protocol to evaluate treatment efficacy of nivolumab based on serum-soluble PD-L1 concentration for patients with ...)
353. New Combination Therapy Findings from University of Texas M.D. Anderson Cancer Center Outlined (Combination Anti-ctla-4 Plus Anti-pd-1 Checkpoint Blockade Utilizes Cellular Mechanisms Partially Distinct From Monotherapies)
354. University of Modena and Reggio Emilia Reports Findings in Cutaneous Melanoma (Adjuvant therapy for cutaneous melanoma: a systematic review and network meta-analysis of new therapies)
355. Reports from Bristol-Myers Squibb Company Provide New Insights into Solid Cancer (Population pharmacokinetics of ipilimumab in combination with nivolumab in patients with advanced solid tumors)
356. New Cancer Data Have Been Reported by Researchers at Bristol-Myers Squibb Company (Population Pharmacokinetics of Nivolumab in Combination With Ipilimumab in Patients With Advanced Malignancies)
357. New Findings Reported from S. Vuyyala and Co-Authors Describe Advances in Carcinomas (Complete Remission of Bone Metastases in Renal Cell Carcinoma with Nivolumab)
358. Global Small Cell Lung Cancer Pipeline Report 2019: Diverse First-in-Class Pipeline Shows Promise of Targeted Therapies to Treat Aggressive Disease - ResearchAndMarkets.com
359. Study Data from University of Modena and Reggio Emilia Provide New Insights into Carcinomas (Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature)
360. Studies from A. Figueiredo and Colleagues Reveal New Findings on Non-Small Cell Lung Cancer [Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC)]
361. New Cancer Findings Reported from Oncology Department (Tumour flare reaction in cancer treatments: a comprehensive literature review)
362. Findings on Melanoma Reported by Investigators at IRCCS Foundation National Cancer Institute (Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience)
363. Researchers from National Institute of Dental and Craniofacial Research Report Recent Findings in Sjogren's Syndrome (Sicca Syndrome Associated With Immune Checkpoint Inhibitor Therapy)
364. Reports from Humanitas Clinical and Research Center Describe Recent Advances in Non-Small Cell Lung Cancer (Nivolumab in disadvantaged subgroups of metastatic non-small-cell lung cancer patients: a single-institution experience)
365. Investigators at Henan Provincial People's Hospital Have Published New Data on Carcinomas (Role of immune checkpoint inhibitor-based therapies for metastatic renal cell carcinoma in the first-line setting: A Bayesian network analysisResearch in ...)
366. Researchers at Icahn School of Medicine at Mount Sinai Have Published New Data on Adrenal Insufficiency (Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis)
367. Study Results from Peking Union Medical College Hospital Broaden Understanding of Myocarditis (Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data)
368. Researchers Submit Patent Application, 'Novel Alkylating Agent', for Approval (USPTO 20190262457)
369. Researchers Submit Patent Application, 'Immunotherapy Markers And Uses Therefor', for Approval (USPTO 20190237196)
370. Researchers at University of Genoa Report New Data on Non-Small Cell Lung Cancer (Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer)
371. Data on Brain Metastasis Reported by Researchers at Department of Medical Oncology (Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme)
372. Researchers at Department of Internal Medicine Report New Data on Lambert-Eaton Myasthenic Syndrome (Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with Small-Cell Lung Cancer)
373. Reports Summarize Melanoma Findings from University of Rochester Medical Center (Immune checkpoint inhibitors in older adults with melanoma or cutaneous malignancies: The Wilmot Cancer Institute experience)
374. Findings from M. Weller and Co-Researchers Advance Knowledge in Glioblastomas (How we treat glioblastoma)
375. Report Summarizes Melanoma Study Findings from Bristol-Myers Squibb Company (Nivolumab Clearance Is Stationary in Patients With Resected Melanoma on Adjuvant Therapy: Implications of Disease Status on Time-Varying Clearance)
376. New Cholangiocarcinoma Data Have Been Reported by Investigators at University of Alabama at Birmingham. (Prolonged Response to Anti-PD-1 Antibody Therapy in Chemotherapy-Refractory Cholangiocarcinoma With High Tumor Mutational Burden)
377. Data on Cancer Detailed by Researchers at Medical Oncology Service (Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients)
378. New Lymphoma Findings from L. de Forceville and Co-Researchers Reported (Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases)
379. Findings from M. Filetti and Co-Authors in the Area of Aplastic Anemia Reported (Unexpected serious aplastic anemia from PD-1 inhibitors: beyond what we know)
380. Cabometyx cabozantinib; Exelixis/Ipsen/Takeda Drug Overview & Product Profiles 2019 - ResearchAndMarkets.com
381. Researchers from H. Lee Moffitt Cancer Center and Research Institute Report Recent Findings in Papillomatosis (Clinical Activity of Nivolumab for Human Papilloma Virus-Related Juvenile-Onset Recurrent Respiratory Papillomatosis)
382. New Monoclonal Antibodies Study Findings Recently Were Reported by E. Jaccoulet and Co-Researchers (Forced degradation of monoclonal antibodies after compounding: impact on routine hospital quality control)
383. Small-Cell Lung Cancer SCLC Market Spotlight Report 2019 - ResearchAndMarkets.com
384. Japan Pharma, Healthcare, Regulatory and Reimbursement Landscape 2019-2020 - ResearchAndMarkets.com
385. Research and Markets Offers Report: Market Spotlight: Small-Cell Lung Cancer (SCLC)
386. Recent Findings from Sarah Cannon Research Institute Provide New Insights into Non-Small Cell Lung Cancer [Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced ...]
387. Recent Findings in Immunoglobulins Described by Researchers from University of Lausanne Hospital (Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway)
388. Study Results from University of California - Davis Broaden Understanding of Lung Cancer (Squamous Cell Transformation of Primary Lung Adenocarcinoma In a Patient With Eml4-alk Fusion Variant 5 Refractory To Alk Inhibitors)
389. New Data from Bristol-Myers Squibb Company Illuminate Findings in Solid Cancer (Model-Based Population Pharmacokinetic Analysis of Nivolumab in Chinese Patients With Previously Treated Advanced Solid Tumors, Including Non-Small Cell Lung Cancer)
390. Researchers Submit Patent Application, 'Combining Cd27 Agonists And Immune Checkpoint Inhibition For Immune Stimulation', for Approval (USPTO 20190135933)
391. Reports from University Hospital Essen Highlight Recent Findings in Non-Small Cell Lung Cancer (Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with ...)
392. Investigators from Otto Von Guericke University Report New Data on Immunotherapy (Implications of Immunotherapy In Hepatobiliary Tumors)
393. Findings on Non-Small Cell Lung Cancer Discussed by O. Bylicki and Co-Researchers [First-line Treatment of Non-small-cell Lung Cancer (Nsclc) With Immunecheckpoint Inhibitors]
394. New Rheumatoid Arthritis Findings from Janssen Pharmaceutical Companies Described (Immune Checkpoint Inhibitor Pd-1 Pathway Is Down-regulated In Synovium At Various Stages of Rheumatoid Arthritis Disease Progression)
395. New Findings from D. Fujimoto and Co-Authors Describe Advances in Non-Small Cell Lung Cancer (Pseudoprogression In Previously Treated Patients With Non-small Cell Lung Cancer Who Received Nivolumab Monotherapy)
396. New Lung Cancer Findings from Central South University Reported (EGFR exon 21 L858R as an acquired resistance mechanism to nivolumab in a lung cancer patient originally driver gene-negative)
397. Why Do Patients Agree To or Decline Adjuvant Immunotherapy and Are They Satisfied With Their Decision?
398. A Multicenter, Open-Label, Exploratory Platform Study to Evaluate Biomarkers and Immunotherapy Combinations for the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
399. Patent Issued for Treatment Of PD-L1-Negative Melanoma Using An anti-PD-1 Antibody And An anti-CTLA-4 Antibody (USPTO 10,174,113)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.